JP2005512558A - 癌のための新規の組成物および方法 - Google Patents

癌のための新規の組成物および方法 Download PDF

Info

Publication number
JP2005512558A
JP2005512558A JP2003553988A JP2003553988A JP2005512558A JP 2005512558 A JP2005512558 A JP 2005512558A JP 2003553988 A JP2003553988 A JP 2003553988A JP 2003553988 A JP2003553988 A JP 2003553988A JP 2005512558 A JP2005512558 A JP 2005512558A
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
gene
sequence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003553988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512558A5 (enExample
Inventor
デービッド ダブリュー． モーリス，
Original Assignee
サイグレス ディスカバリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイグレス ディスカバリー， インコーポレイテッド filed Critical サイグレス ディスカバリー， インコーポレイテッド
Publication of JP2005512558A publication Critical patent/JP2005512558A/ja
Publication of JP2005512558A5 publication Critical patent/JP2005512558A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
JP2003553988A 2001-12-20 2002-12-20 癌のための新規の組成物および方法 Pending JP2005512558A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/034,650 US20030216558A1 (en) 2000-12-22 2001-12-20 Novel compositions and methods for cancer
PCT/US2002/041776 WO2003053224A2 (en) 2001-12-20 2002-12-20 Novel compositions and methods for cancer

Publications (2)

Publication Number Publication Date
JP2005512558A true JP2005512558A (ja) 2005-05-12
JP2005512558A5 JP2005512558A5 (enExample) 2006-01-26

Family

ID=21877742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003553988A Pending JP2005512558A (ja) 2001-12-20 2002-12-20 癌のための新規の組成物および方法

Country Status (6)

Country Link
US (1) US20030216558A1 (enExample)
EP (1) EP1469769A4 (enExample)
JP (1) JP2005512558A (enExample)
AU (2) AU2002364052B2 (enExample)
CA (1) CA2470844A1 (enExample)
WO (1) WO2003053224A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064377A1 (en) * 2000-11-06 2003-04-03 Yongming Sun Compositions and methods relating to prostate specific genes and proteins
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
GB0703887D0 (en) * 2007-02-28 2007-04-11 Bakhiet Abdelmoiz Immune system mediator
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
CN119757761A (zh) * 2024-12-16 2025-04-04 新疆医科大学第一附属医院 一种鉴别诊断活动性肺结核的生物标志物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2416292A1 (en) * 2000-06-29 2002-01-10 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
US20030044812A1 (en) * 2001-01-18 2003-03-06 Walker Michael G. Cell differentiation cDNAs induced by retinoic acid
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US20030049623A1 (en) * 2001-07-18 2003-03-13 Shi Huang PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use

Also Published As

Publication number Publication date
WO2003053224A2 (en) 2003-07-03
EP1469769A4 (en) 2008-06-18
AU2008203436A1 (en) 2008-08-21
CA2470844A1 (en) 2003-07-03
US20030216558A1 (en) 2003-11-20
AU2002364052A1 (en) 2003-07-09
WO2003053224A3 (en) 2003-09-04
EP1469769A2 (en) 2004-10-27
AU2002364052B2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
JP2006507794A (ja) 癌のための新規の組成物および方法
US20020042067A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
JP2009195249A (ja) 癌のための新規の組成物および方法
JP2004510951A (ja) 結腸直腸癌を診断する新規の方法、組成物、結腸直腸癌調節のためのスクリーニング法
JP2005512558A (ja) 癌のための新規の組成物および方法
JP2009195241A (ja) 癌のための新規の組成物および方法
JP2009225807A (ja) Ｐｒｌｒの変化した発現に関連する癌における新規組成物および方法
US20060211015A1 (en) Novel compositions and methods for cancer
EP1469870A2 (en) Novel compositions and methods for cancer
JP2009195243A (ja) Ｔｂｘ２１の変更された発現に関連する癌における新規組成物および方法
US20030022255A1 (en) Novel compositions and methods for breast cancer
JP2009195244A (ja) Ｍｃｍ３ａｐの変更された発現に関連する癌における新規組成物および方法
JP2009232852A (ja) Ｋｃｎｊ９の異常発現に関連する癌における新規組成物および方法
JP2009195242A (ja) Ｐｒｄｍ１１の変更された発現に関連する癌における新規組成物および方法
JP2005506514A (ja) 結腸直腸ガンおよび／または乳ガンの診断方法、結腸直腸ガンおよび／または乳ガンのモジュレータの組成物およびスクリーニング法
JP2004537710A (ja) 乳癌の診断及び治療の新規方法、組成物及び乳癌調節剤用の選別方法
AU2003230669A1 (en) Novel compositions and methods in cancer associated with altered expression of tbx21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090612